Last reviewed · How we verify
NCT03984370
Dasiglucagon in the Treatment of Postprandial Hypoglycaemia After Roux-en-Y Gastric Bypass
Phase 2 trial testing ZP4207 in Hyperinsulinemic Hypoglycemia in 10 participants. Completed in 26 February 2020.
26 February 2020
Quick facts
| Lead sponsor | University Hospital, Gentofte, Copenhagen |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 18 September 2019 |
| Primary completion | 26 February 2020 |
| Estimated completion | 26 February 2020 |
| Sites | 1 location across Denmark |
Drugs / interventions tested
- ZP4207 — full drug profile →
- Placebo (saline)
Conditions studied
- Hyperinsulinemic Hypoglycemia — all drugs for Hyperinsulinemic Hypoglycemia →
- Postprandial Hypoglycemia — all drugs for Postprandial Hypoglycemia →
Sponsor
University Hospital, Gentofte, Copenhagen
Who can join
Adults 18 to 75, any sex, with Hyperinsulinemic Hypoglycemia or Postprandial Hypoglycemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is investigating the effect of a novel glucagon analogue administration in gastric bypass operated individuals, who are reactive hypoglycemic.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
56<sup>th</sup> EASD Annual Meeting of the European Association for the Study of Diabetes : 21-25 September 2020.
· 2020 · cited 9× · PMID 32840677 · DOI 10.1007/s00125-020-05221-5
Verify or expand the search:
- PubMed search for NCT03984370
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hyperinsulinemic Hypoglycemia
Currently open trials in the same condition.
- NCT05597475 — GLP1R-imaging in Post-RYGB Hypoglycemia · NA · recruiting
Other University Hospital, Gentofte, Copenhagen trials
Trials by the same sponsor.
- NCT07171723 — Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment · Phase 1, PHASE2 · recruiting
- NCT06934473 — Effects of Endogenous GIP on Postprandial Blood Pressure in Healthy Individuals · NA · recruiting
- NCT06845033 — Effects of Antagonizing the Ghrelin Receptor on Brain Food Cue Reactivity in Obesity · NA · not yet recruiting
- NCT06787001 — Understanding How Gut and Brain Barriers Are Linked to Inflammation in Obesity · completed
- NCT06881459 — The Effect of Oxytocin on the Alpha Cell Response to Hypoglycaemia in Patients With Type 1 Diabetes · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03984370 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Gentofte, Copenhagen
- Last refreshed: 31 March 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03984370.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing